Cardiorenal Disease in COVID-19 Patients.
Muhtasham SifaatPinak PatelRazan SheikhDawood GhaffarHitesh VaishnavLudmila NaharSonia RupaniSyed QuadriPublished in: Journal of the renin-angiotensin-aldosterone system : JRAAS (2022)
Coronavirus disease 2019 (COVID-19) is an illness caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Mutations in the genetic coding and the variations in the spike proteins are critical for the virus's mechanism of facilitating fusion with the human host, making the disease more severe. Recent research indicates that comorbidities including diabetes, hypertension, renal disease, heart failure, and atherosclerosis play a significant role in the severity and high mortality rates of (COVID-19), suggesting that perhaps the metabolic syndrome and its components are associated with COVID-19 morbidity. Primarily, angiotensin-converting enzyme 2 (ACE2) receptor is identified as the entrance receptor of SARS-CoV-2. Increased ACE2 expression, endothelial dysfunction plays a vital role in the progression and severity of complications developed due to COVID-19. In this review, we will discuss the association and management of cardiorenal disease and COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- angiotensin converting enzyme
- heart failure
- metabolic syndrome
- angiotensin ii
- cardiovascular disease
- blood pressure
- type diabetes
- risk factors
- poor prognosis
- endothelial cells
- insulin resistance
- cardiovascular events
- gene expression
- coronary artery disease
- binding protein
- left ventricular
- uric acid
- genome wide
- copy number
- cardiac resynchronization therapy